Capnia, Inc. (NASDAQ: CAPN) develops diagnostic and therapeutic products based on its proprietary technology for the precision metering of gas flow. Operating primarily in the U.S., the company offers CoSense for the diagnosis of excessive hemolysis in neonates, a condition that causes long-term developmental disability due to the degradation of red blood cells. It also develops Serenz, a therapeutic product candidate that has completed phase II clinical trials for the treatment of symptoms related to allergic rhinitis. For more information, visit the company’s website at www.capnia.com.